Approach to Polyuria - อ.ฉัตรชัย กรีพละ
Renal replacement therapy in ARF - อ.ฉัตรชัย กรีพละ
Early goal-directed therapy-อ.สุทัศน์
How to prevent VAP-อ.สุทัศน์
Lecture : LFT interpretation 4th year student อ.อรพิน
Lecture : Practicle point in Thalassemia อ.จันทนา
Lecture: OSCE for GI system อ.ปิยะนันท์
Lecture : Infective endocarditis อ.ไพโรจน์
code จ้า
เพื่อความสะดวกครับ 
Lecture : Introduction to cardiovasculr exam & evaluation for student อ.ไพโรจน์
Lecture : Hepatobiliary tract disease อ.อรพิน
Lecture : Acute liver failure อ.ปิยะนันท์
Lecture : Approach to headache for medical student อ.นฤมล
Lecture : Syncope for medical student อ.วรวุฒิ
Lecture : Cardiovascular drugs for medical student อ.ไพโรจน์
human carcinogen reviews
from lancet oncology
Diagnosis and Management of Acute stroke
Herceptin improves event-free survival in women with HER2-positive locally advanced or inflammatory breast cancer
ST LOUIS (MD Consult) - Herceptin (trastuzumab) should be offered to patients with HER2-positive locally advanced or inflammatory breast cancer alongside chemotherapy, researchers report in the January 30, 2010, issue of The Lancet.Lancet 2010;375:377-384, 349-350
The article is written by Dr Luca Gianni, Fondazione, IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and colleagues.
This new research looks specifically at the effect of herceptin on locally advanced and inflammatory breast cancers. Locally advanced breast cancer accounts for 6-10% of new cases of breast cancer and has a worse prognosis than does early operable disease, although patients with locally advanced disease have a better outlook than do those with distant metastases. Inflammatory breast cancer is a rare clinical and pathological subtype that follows an aggressive course and needs systemic therapy even when apparently localized.
Amplification or overexpression, or both, of human epidermal growth factor receptor-2 (HER2, also known as ERBB2), is present in around 22% of early breast cancers, 35% of locally advanced and metastatic tumors, and 40% of inflammatory breast cancers. It is associated with aggressive disease and poor prognosis. Patients with HER2-positive locally advanced or inflammatory breast cancer are therefore in particular need of effective treatment. In this study, the authors assessed event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of herceptin.
The authors compared 1 year of treatment with herceptin (given as neoadjuvant and adjuvant treatment; n=117) with no herceptin (118), in women with HER2-positive locally advanced or inflammatory breast cancer treated with a neoadjuvant chemotherapy regimen consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil. A parallel cohort of 99 patients with HER2-negative disease was included and treated with the same chemotherapy regimen. The primary endpoint was event-free survival.
Herceptin significantly improved event-free survival in patients with HER2-positive breast cancer (3-year event-free survival, 71% with herceptin vs 56% without). Herceptin was well tolerated and, despite concurrent administration with doxorubicin, only 2 patients (2%) developed symptomatic cardiac failure. Both responded to cardiac drugs.
“The addition of neoadjuvant and adjuvant trastuzumab (herceptin) to neoadjuvant chemotherapy should be considered for women with HER2-positive locally advanced or inflammatory breast cancer to improve event-free survival, survival, and clinical and pathological tumor responses,” the authors said.
In an accompanying comment, Dr Melanie D Seal, and Dr Stephen K Chia, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, said, “Almost all new systemic agents being studied in cancer are targeted agents. Understanding the target, and downstream and redundant effects, is essential if we truly are moving to personalized medicine. Adjuvant studies require thousands of women to show survival benefits, at high cost and often long follow-up. Studies such as NOAH illustrate the benefits and potential of neoadjuvant trials and should challenge the dogma of our current strategies of therapeutic trials in early-stage breast cancer.”
Histology Matters: Individualizing Treatment in NSCLC
Interestingly, a recent analysis of the Surveillance, Epidemiology, and End Results data from 1990 – 2005 does demonstrate a significant but modest improvement in the treatment of stage IV lung cancer over the last 15 years, with 1-year survival rates improving by 6% and 2-year survival rates improving by 3%. Within this recent analysis, it is clear that different histologic subtypes of NSCLC have had differential improvements.
อ่านต่อใน The Oncologist
http://theoncologist.alphamedpress.org/cgi/reprint/15/1/3
4 กุมภาพันธ์ “วันมะเร็งโลก”
4 กุมภาพันธ์ “วันมะเร็งโลก”
สถาบันมะเร็งแห่งชาติ และสมาคมโรค
มะเร็งแห่งประเทศไทยในพระบรมราชินูปถัมภ์ ขอเชิญผู้สนใจทุกท่าน
สมัครเข้าร่วมฟังการเสวนา เรื่อง”มะเร็งที่เกิดจากการติดเชื้อ”โดยทีม
แพทย์ผู้เชี่ยวชาญ จากสมาคมวิชาชีพแพทย์สาขาต่างๆ ฟรี ในวันที่
4 กุมภาพันธ์ 2553 เวลา 13.00-15.30 น. ณ.ห้องแกรนด์บอลรูม
ชั้น 4 โรงแรมมิราเคิลแกรนด์ กรุงเทพฯ